GleamWall
中文EN

RDHL RedHill Biopharma Ltd. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1553846

Financial factors as of 2021-12-31 (FY2021), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY33.2%
TTM net income YoY-28.3%
TTM EPS YoY0.0%
Revenue 3-yr CAGR117.3%
Net income 3-yr CAGR—

Margins

Gross margin42.4%
Operating margin-94.6%
Net margin-114.0%
FCF margin-76.0%
EBITDA margin—

Returns

ROE-859.7%
ROA-54.1%
ROIC (approx.)-99.4%
Asset turnover0.47x

Leverage & solvency

Liabilities / assets95.1%
Debt / equity9.42x
Current ratio1.09x
Interest coverage-4.87x

Cash quality & payout

Operating cash flow / net income0.67x
Accruals ratio-18.1%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2024*2024-12-31FY2023*2023-12-31
Income statement
Revenue$8.04M$6.53M
Cost of revenue$3.19M$3.46M
Gross profit$4.85M$3.07M
R&D expense$1.59M$3.53M
SG&A expense$9.57M$16.22M
Operating income-$14.61M$12.63M
Interest expense$2.06M$9.61M
Net income-$8.27M$23.92M
EPS (basic)0.000.01
EPS (diluted)0.000.01
Balance sheet
Cash & equivalents$4.62M$5.57M
Receivables$2.54M$2.59M
Inventory$3.65M$4.39M
Current assets$11.91M$16.14M
PP&E, netmay include right-of-use assets (IFRS)$135,000$193,000
Intangibles$5.55M$5.58M
Total assets$18.04M$23.05M
Current liabilities$22.22M$19.98M
Total liabilities$22.73M$20.98M
Shareholders' equity-$4.68M$2.07M
Cash flow statement
Operating cash flow-$9.37M-$35.82M
Capital expenditure$9,000$11,000
Free cash flow-$9.38M-$35.83M
Investing cash flow-$9,000$4,000
Financing cash flow$8.42M$21.44M
Stock-based compensation$665,000$1.65M

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.